FindTrial
Sign In

Renal angiogram

DIAGNOSTIC_TEST4 trials

Sponsors

Medtronic Vascular, ReCor Medical, Inc., Saskatchewan Health Authority - Regina Area, Otsuka Medical Devices Co., Ltd. Japan

Conditions

Cardiovascular DiseasesHypertensionLoin Pain-Hematuria SyndromeUncontrolled HypertensionVascular Diseases

Unknown Phase

SYMPLICITY HTN-3 Renal Denervation in Patients With Uncontrolled Hypertension
CompletedNCT01418261
Medtronic VascularUncontrolled Hypertension
Start: 2011-09-30End: 2017-02-17Updated: 2017-04-26
The RADIANCE II Pivotal Study: A Study of the ReCor Medical Paradise System in Stage II Hypertension
Active, not recruitingNCT03614260
ReCor Medical, Inc.Cardiovascular Diseases, Hypertension, Vascular Diseases
Start: 2018-12-14End: 2027-07-31Target: 225Updated: 2025-04-04
Prairie Loin Pain Hematuria Syndrome Renal Denervation Study: A Feasibility Study
Active, not recruitingNCT04332731
Saskatchewan Health Authority - Regina AreaLoin Pain-Hematuria Syndrome
Start: 2020-12-01End: 2024-12-31Target: 10Updated: 2024-04-16
A Clinical Study of the Paradise™ Renal Denervation System in Patients With Hypertension (RADIANCE-HTN DUO)
Active, not recruitingNCT05326230
Otsuka Medical Devices Co., Ltd. JapanCardiovascular Diseases, Hypertension, Vascular Diseases
Start: 2022-07-01End: 2032-12-01Target: 154Updated: 2026-04-15

Related Papers

Patient-Level Pooled Analysis of Endovascular Ultrasound Renal Denervation or a Sham Procedure 6 Months After Medication Escalation: The RADIANCE Clinical Trial Program
Circulation2023-10-2632 citations
Endovascular Ultrasound Renal Denervation to Treat Hypertension
JAMA2023-02-28163 citations
Patient-Level Pooled Analysis of Ultrasound Renal Denervation in the Sham-Controlled RADIANCE II, RADIANCE-HTN SOLO, and RADIANCE-HTN TRIO Trials
JAMA Cardiology2023-02-2877 citations
Long-term outcomes after catheter-based renal artery denervation for resistant hypertension: final follow-up of the randomised SYMPLICITY HTN-3 Trial.
2022-09-18120 citations
Feasibility Study of a Randomized Controlled Trial Investigating Renal Denervation as a Possible Treatment Option in Patients With Loin Pain Hematuria Syndrome
Canadian Journal of Kidney Health and Disease2020-01-012 citations
Regression to the Mean in SYMPLICITY HTN-3: Implications for Design and Reporting of Future Trials.
2016-11-0134 citations
Reduced blood pressure-lowering effect of catheter-based renal denervation in patients with isolated systolic hypertension: data from SYMPLICITY HTN-3 and the Global SYMPLICITY Registry
European Heart Journal2016-07-28143 citations
Effect of Catheter-Based Renal Denervation on Morning and Nocturnal Blood Pressure
Hypertension2015-10-0648 citations
12-month blood pressure results of catheter-based renal artery denervation for resistant hypertension: the SYMPLICITY HTN-3 trial.
2015-04-0174 citations
Predictors of blood pressure response in the SYMPLICITY HTN-3 trial
European Heart Journal2014-11-16534 citations
Similar 12-Month BP Reductions with Renal Denervation and Sham Procedure
MD Conference Express2014-10-01
Multiple Factors Examined for Contributing to SYMPLICITY HTN-3 Failure
MD Conference Express2014-08-01
Impact of renal denervation on 24-hour ambulatory blood pressure: results from SYMPLICITY HTN-3.
2014-05-20140 citations
A Controlled Trial of Renal Denervation for Resistant Hypertension
New England Journal of Medicine2014-03-292132 citations